Table 2.

Treatment exposure.

Treatment exposure	Olaparib alone (n = 23)	Olaparib plus durvalumab (n = 22)
Olaparib
Median (range) of olaparib cycles	5 (2–19)	5.5 (1–24)
Patients with olaparib dose interruption	18 (78)	18 (82)
Due to AE	9 (39)	10 (45)
Lasting ≥3 days	8 (35)	9 (41)
Lasting ≥14 days	3 (13)	1 (5)
Patients with olaparib dose reductiona	4 (17)	2 (9)
Due to AE	3 (13)	2 (9)
Due to physician decision	2 (9)	0
Patients with olaparib permanently discontinued	20 (87)	16 (73)
Olaparib treatment ongoing	3 (13)	6 (27)
Durvalumab
Median (range) of durvalumab cycles	—	4 (1–24)
Patients with ≥1 durvalumab cycle omitted	—	2 (9)
Patients with durvalumab permanently discontinued	—	16 (73)
Durvalumab treatment ongoing	—	6 (27)

Note: Data are n (%) unless otherwise specified.

Abbreviation: AE, adverse event.

^aMore than one reason possible.